



Summary of Studies Supporting USDA Product Licensure

Establishment Name	Merial, Inc.
USDA Vet Biologics Establishment Number	298
Product Code	17H1.R2
True Name	Marek's Disease-Newcastle Disease Vaccine, Serotypes 2 & 3, Live Virus, Live Marek's Disease Vector
Tradenname(s) / Distributor or Subsidiary (if different from manufacturer)	NEWXXITEK HVT+ND & SB1 - No distributor specified
Date of Compilation Summary	November 06, 2019

Disclaimer: Do not use the following studies to compare one product to another. Slight differences in study design and execution can render the comparisons meaningless.

Study Type	Efficacy
Pertaining to	Marek's disease virus
Study Purpose	Demonstrate efficacy against very virulent Marek's Disease virus
Product Administration	1 dose by in ovo route
Study Animals	18- to 19-day-old embryos were divided into 4 groups Group 1 vaccinated with test product and challenged Group 2 sham vaccinated and challenged (control) Group 3 sham vaccinated non-challenged (control) Group 4 vaccinated with HVT vaccine and challenged
Challenge Description	Serotype 1, RB1B very virulent Marek's disease virus
Interval observed after challenge	Birds observed daily for clinical signs for 45 days post challenge
Results	Vaccinates and controls were evaluated in terms of Marek's disease clinical signs and/or grossly observable lesions per the criteria in 9 CFR 113.330(c). Birds with clinical signs and/or observable lesions: Group 1: 5/28 Group 2: 34/34 Group 3: 0/25 Group 4: 18/34 Requirements of 9 CFR 113.330(c) were met. Raw data on attached page
USDA Approval Date	March 25, 2014

Group/Bird	Paralysis	Locomotive	Emaciation	De-pression	Liver	Spleen	Heart	Muscle	Gonads	Kidneys	Other Gross Lesions	Comments
1/1			X						X			
1/2									X	X		
1/3		X	X						X	X		
1/4									X			
1/5									X	X		
2/1				X		X			X			
2/2				X	X	X	X			X		
2/3		X							X	X		
2/4				X	X		X					
2/5				X	X	X				X		
2/6										X		
2/7				X	X	X	X					
2/8			X			X				X		
2/9				X					X	X		
2/10			X			X	X		X	X		
2/11				X	X				X	X		
2/12				X	X	X	X			X		
2/13		X		X	X	X						
2/14				X	X	X	X					
2/15										X		
2/16			X	X				X	X	X		
2/17				X		X				X		
2/18				X	X		X		X	X		
2/19			X	X		X			X	X		
2/20				X				X	X			
2/21					X	X				X		
2/22			X	X		X			X	X		
2/23				X		X				X		
2/24				X			X		X	X		
2/25				X		X			X	X		
2/26				X								
2/27				X						X		
2/28		X		X						X		
2/29				X		X	X			X		
2/30				X		X	X			X	X	Intestinal tract
2/31		X	X					X	X	X		
2/32				X	X	X				X		
2/33				X		X				X		
2/34				X	X	X				X		
4/1					X	X	X		X	X		

Group/Bird	Paralysis	Locomotive	Emaciation	De- pression	Liver	Spleen	Heart	Muscle	Gonads	Kidneys	Other Gross Lesions	Comments
4/2								X	X	X	X	Intestinal tract (other)
4/3									X			
4/4	X								X			
4/5			X	X			X			X	X	Intestinal tract
4/6				X		X		X	X			X Intestinal tract
4/7												X Intestinal tract
4/8									X			X Intestinal tract
4/9			X	X		X			X	X		
4/10										X		
4/11		X							X			
4/12			X									X Intestinal tract
4/13		X		X			X		X			
4/14		X		X			X	X		X		
4/15		X		X			X	X		X		
4/16		X							X	X		
4/17							X			X		
4/18					X	X	X			X		

No clinical signs or lesions were observed in remaining birds in study.

Study Type	Efficacy
Pertaining to	Marek's disease virus
Study Purpose	Demonstrate efficacy against very virulent Marek's Disease virus
Product Administration	1 dose by Subcutaneous route
Study Animals	Day-old chicks divided into 4 groups Group 1 vaccinated with test product and challenged Group 2 sham vaccinated and challenged (control) Group 3 sham vaccinated non-challenged (control) Group 4 vaccinated with HVT vaccine and challenged
Challenge Description	Serotype 1, RB1B very virulent Marek's disease virus
Interval observed after challenge	Birds observed daily for clinical signs for 45 days post challenge
Results	Vaccinates and controls were evaluated in terms of Marek's disease clinical signs and/or grossly observable lesions per the criteria in 9 CFR 113.330(c). Birds with clinical signs and/or observable lesions: Group 1: 5/35 Group 2: 35/35 Group 3: 0/25 Group 4: 9/34 Requirements of 9 CFR 113.330(c) were met. Raw data on attached page
USDA Approval Date	April 3, 2014

Group/ Bird	Paralysis	Locomotive	Emaciation	Depression	Other Clinical Signs	Liver	Spleen	Heart	Muscle	Gonads	Kidneys	Other Gross Lesions	Comments
1/1												X	Intestinal tract
1/2						X	X	X		X	X		
1/3								X		X			
1/4										X			
1/5		X		X		X				X	X		
2/1				X			X				X		
2/2		X		X		X		X			X		
2/3				X			X			X			
2/4				X			X						
2/5		X		X						X			
2/6				X			X	X					
2/7				X		X	X	X					
2/8											X		
2/9				X	X								Torticollis
2/10							X				X		
2/11			X	X							X		
2/12				X						X	X		
2/13				X									
2/14				X			X				X		
2/15				X									
2/16		X		X			X	X					
2/17				X			X						
2/18			X	X			X	X	X		X		
2/19		X		X									
2/20				X		X	X				X		
2/21				X		X	X				X		
2/22								X		X		X	Intestinal tract
2/23				X			X		X		X		
2/24		X				X	X	X		X	X		
2/25				X							X		
2/26				X									Large retained yolk
2/27				X			X				X		
2/28	X												
2/29				X			X				X		
2/30				X				X	X	X	X		
2/31				X			X				X		
2/32				X				X			X		
2/33				X		X	X		X				
2/34				X			X			X			
2/35				X	X								Torticollis
4/1												X	Intestinal tract
4/2		X											

Group/ Bird	Paralysis	Locomotive	Emaciation	Depression	Other Clinical Signs	Liver	Spleen	Heart	Muscle	Gonads	Kidneys	Other Gross Lesions	Comments
4/3										X			
4/4											X		
4/5							X	X		X	X		
4/6				X					X	X	X		
4/7		X	X	X				X	X		X		
4/8										X	X		
4/9		X		X		X			X	X	X		

No clinical signs or lesions were observed in remaining birds in the study.

Study Type	Efficacy
Pertaining to	Newcastle disease virus (NDV)
Study Purpose	Demonstrate efficacy against virulent Newcastle disease
Product Administration	1 dose by subcutaneous route
Study Animals	Day old chicks were divided into 2 groups Group 1 vaccinated and challenged Group 2 sham vaccinated and challenged (control)
Challenge Description	NDV Texas GB
Interval observed after challenge	Birds observed daily for clinical signs for 14 days post challenge
Results	Vaccinates and controls were evaluated in terms of Newcastle disease clinical signs per the criteria in 9 CFR 113.329(c)(4). Birds with clinical signs: Group 1: 0/30 Group 2: 30/30 Requirements of 9 CFR 113.329(c)(4) were met. Raw data on attached page
USDA Approval Date	March 10, 2014

Group/Bird	NDV Result based on clinical signs
2/1	Positive
2/2	Positive
2/3	Positive
2/4	Positive
2/5	Positive
2/6	Positive
2/7	Positive
2/8	Positive
2/9	Positive
2/10	Positive
2/11	Positive
2/12	Positive
2/13	Positive
2/14	Positive
2/15	Positive
2/16	Positive
2/17	Positive
2/18	Positive
2/19	Positive
2/20	Positive
2/21	Positive
2/22	Positive
2/23	Positive
2/24	Positive
2/25	Positive
2/26	Positive
2/27	Positive
2/28	Positive
2/29	Positive
2/30	Positive

Study Type	Efficacy
Pertaining to	Newcastle disease virus (NDV)
Study Purpose	Demonstrate efficacy against virulent Newcastle disease
Product Administration	1 dose by <i>in ovo</i> route
Study Animals	18 to 19 day old embryos were divided into 2 groups Group 3 vaccinated and challenged Group 4 sham vaccinated and challenged (control)
Challenge Description	NDV Texas GB
Interval observed after challenge	Birds observed daily for clinical signs for 14 days post challenge
Results	Vaccinates and controls were evaluated in terms of Newcastle disease clinical signs per the criteria in 9 CFR 113.329(c)(4). Birds with clinical signs: Group 3: 2/39 Group 4: 40/40 Requirements of 9 CFR 113.329(c)(4) were met. Raw data on attached page
USDA Approval Date	March 27, 2014

Group/Bird	Paralysis	Muscular Tremors	NDV Result
3/1		X	Positive
3/2			Positive
4/1			Positive
4/2		X	Positive
4/3			Positive
4/4			Positive
4/5		X	Positive
4/6		X	Positive
4/7		X	Positive
4/8			Positive
4/9			Positive
4/10			Positive
4/11		X	Positive
4/12			Positive
4/13		X	Positive
4/14			Positive
4/15		X	Positive
4/16		X	Positive
4/17		X	Positive
4/18			Positive
4/19		X	Positive
4/20			Positive
4/21		X	Positive
4/22		X	Positive
4/23			Positive
4/24		X	Positive
4/25		X	Positive
4/26			Positive
4/27		X	Positive
4/28			Positive
4/29			Positive
4/30			Positive
4/31			Positive
4/32			Positive
4/33			Positive
4/34		X	Positive
4/35			Positive
4/36		X	Positive
4/37			Positive
4/38			Positive
4/39			Positive
4/40			Positive

Study Type	Safety																																																																																									
Pertaining to	All																																																																																									
Study Purpose	Demonstrate safety of product under typical use conditions																																																																																									
Product Administration	1 dose by either the <i>in ovo</i> or subcutaneous route																																																																																									
Study Animals	Poultry, 18 to 19 day-old embryos or day-old chicks. 75,600 were vaccinated by <i>in ovo</i> route, 48,029 were vaccinated by subcutaneous route and 181,400 were kept as controls treated by the typical site vaccination program. Animals were observed daily for mortality through 21 days after vaccination.																																																																																									
Challenge Description	Not applicable																																																																																									
Interval observed after challenge	Not applicable																																																																																									
Results	<p>No adverse reactions attributable to the vaccine were noted.</p> <table border="1"> <thead> <tr> <th>Location</th> <th>Treatment</th> <th>Total Placed</th> <th>21 Day Mortality</th> <th>% Mortality</th> <th>% Hatchability</th> </tr> </thead> <tbody> <tr> <td>1</td> <td><i>In ovo</i></td> <td>22,600</td> <td>794</td> <td>3.5</td> <td>74.7</td> </tr> <tr> <td rowspan="2">1</td> <td>Control</td> <td rowspan="2">24,700</td> <td rowspan="2">721</td> <td rowspan="2">2.9</td> <td rowspan="6">87.4</td> </tr> <tr> <td><i>In ovo</i></td> </tr> <tr> <td rowspan="2">1</td> <td>Control</td> <td rowspan="2">24,700</td> <td rowspan="2">815</td> <td rowspan="2">3.3</td> </tr> <tr> <td><i>In ovo</i></td> </tr> <tr> <td rowspan="2">1</td> <td>Control</td> <td rowspan="2">24,700</td> <td rowspan="2">679</td> <td rowspan="2">2.7</td> </tr> <tr> <td><i>In ovo</i></td> </tr> <tr> <td>2</td> <td><i>In ovo</i></td> <td>20,200</td> <td>398</td> <td>2</td> <td rowspan="2">89.3</td> </tr> <tr> <td>2</td> <td><i>In ovo</i></td> <td>20,300</td> <td>369</td> <td>1.8</td> </tr> <tr> <td rowspan="2">2</td> <td>Control</td> <td rowspan="2">19,100</td> <td rowspan="2">410</td> <td rowspan="2">2.1</td> <td rowspan="2">86.6</td> </tr> <tr> <td><i>In ovo</i></td> </tr> <tr> <td rowspan="2">2</td> <td>Control</td> <td rowspan="2">19,100</td> <td rowspan="2">678</td> <td rowspan="2">3.5</td> <td rowspan="2">N/A</td> </tr> <tr> <td>SQ</td> </tr> <tr> <td rowspan="2">2</td> <td>Control</td> <td rowspan="2">19,100</td> <td rowspan="2">791</td> <td rowspan="2">4.1</td> <td rowspan="2">N/A</td> </tr> <tr> <td>SQ</td> </tr> <tr> <td>3</td> <td>SQ</td> <td>24,000</td> <td>542</td> <td>2.3</td> <td>N/A</td> </tr> <tr> <td>3</td> <td>SQ</td> <td>24,029</td> <td>267</td> <td>1.1</td> <td>N/A</td> </tr> <tr> <td rowspan="2">3</td> <td>Control</td> <td rowspan="2">25,000</td> <td rowspan="2">332</td> <td rowspan="2">1.3</td> <td rowspan="2">N/A</td> </tr> <tr> <td>SQ</td> </tr> <tr> <td rowspan="2">3</td> <td>Control</td> <td rowspan="2">25,000</td> <td rowspan="2">325</td> <td rowspan="2">1.3</td> <td rowspan="2">N/A</td> </tr> <tr> <td>SQ</td> </tr> </tbody> </table> <p>N/A is not applicable</p>	Location	Treatment	Total Placed	21 Day Mortality	% Mortality	% Hatchability	1	<i>In ovo</i>	22,600	794	3.5	74.7	1	Control	24,700	721	2.9	87.4	<i>In ovo</i>	1	Control	24,700	815	3.3	<i>In ovo</i>	1	Control	24,700	679	2.7	<i>In ovo</i>	2	<i>In ovo</i>	20,200	398	2	89.3	2	<i>In ovo</i>	20,300	369	1.8	2	Control	19,100	410	2.1	86.6	<i>In ovo</i>	2	Control	19,100	678	3.5	N/A	SQ	2	Control	19,100	791	4.1	N/A	SQ	3	SQ	24,000	542	2.3	N/A	3	SQ	24,029	267	1.1	N/A	3	Control	25,000	332	1.3	N/A	SQ	3	Control	25,000	325	1.3	N/A	SQ
Location	Treatment	Total Placed	21 Day Mortality	% Mortality	% Hatchability																																																																																					
1	<i>In ovo</i>	22,600	794	3.5	74.7																																																																																					
1	Control	24,700	721	2.9	87.4																																																																																					
	<i>In ovo</i>																																																																																									
1	Control	24,700	815	3.3																																																																																						
	<i>In ovo</i>																																																																																									
1	Control	24,700	679	2.7																																																																																						
	<i>In ovo</i>																																																																																									
2	<i>In ovo</i>	20,200	398	2	89.3																																																																																					
2	<i>In ovo</i>	20,300	369	1.8																																																																																						
2	Control	19,100	410	2.1	86.6																																																																																					
	<i>In ovo</i>																																																																																									
2	Control	19,100	678	3.5	N/A																																																																																					
	SQ																																																																																									
2	Control	19,100	791	4.1	N/A																																																																																					
	SQ																																																																																									
3	SQ	24,000	542	2.3	N/A																																																																																					
3	SQ	24,029	267	1.1	N/A																																																																																					
3	Control	25,000	332	1.3	N/A																																																																																					
	SQ																																																																																									
3	Control	25,000	325	1.3	N/A																																																																																					
	SQ																																																																																									

USDA Approval Date	October 19, 2017
---------------------------	------------------

Study Type	Safety																																																																																												
Pertaining to	All																																																																																												
Study Purpose	Demonstrate safety of product under typical use conditions																																																																																												
Product Administration	1 dose by either the <i>in ovo</i> or subcutaneous route																																																																																												
Study Animals	Poultry, 18 to 19 day-old embryos or day-old chicks. 75,600 were vaccinated by <i>in ovo</i> route, 48,029 were vaccinated by subcutaneous route and 181,400 were kept as controls treated by the typical site vaccination program. Animals were observed daily for mortality through 21 days after vaccination.																																																																																												
Challenge Description	Not applicable																																																																																												
Interval observed after challenge	Not applicable																																																																																												
Results	<p>No adverse reactions attributable to the vaccine were noted.</p> <table border="1"> <thead> <tr> <th>Location</th> <th>Treatment</th> <th>Total Placed</th> <th>21 Day Mortality</th> <th>% Mortality</th> <th>% Hatchability</th> </tr> </thead> <tbody> <tr> <td>1</td> <td><i>In ovo</i></td> <td>22,600</td> <td>794</td> <td>3.5</td> <td>74.7</td> </tr> <tr> <td rowspan="2">1</td> <td>Control</td> <td rowspan="2">24,700</td> <td rowspan="2">721</td> <td rowspan="2">2.9</td> <td rowspan="6">87.4</td> </tr> <tr> <td><i>In ovo</i></td> </tr> <tr> <td rowspan="2">1</td> <td>Control</td> <td rowspan="2">24,700</td> <td rowspan="2">815</td> <td rowspan="2">3.3</td> </tr> <tr> <td><i>In ovo</i></td> </tr> <tr> <td rowspan="2">1</td> <td>Control</td> <td rowspan="2">24,700</td> <td rowspan="2">679</td> <td rowspan="2">2.7</td> </tr> <tr> <td><i>In ovo</i></td> </tr> <tr> <td>2</td> <td><i>In ovo</i></td> <td>20,200</td> <td>398</td> <td>2</td> <td rowspan="2">89.3</td> </tr> <tr> <td>2</td> <td><i>In ovo</i></td> <td>20,300</td> <td>369</td> <td>1.8</td> </tr> <tr> <td rowspan="2">2</td> <td>Control</td> <td rowspan="2">19,100</td> <td rowspan="2">410</td> <td rowspan="2">2.1</td> <td rowspan="4">86.6</td> </tr> <tr> <td><i>In ovo</i></td> </tr> <tr> <td rowspan="2">2</td> <td>Control</td> <td rowspan="2">19,100</td> <td rowspan="2">678</td> <td rowspan="2">3.5</td> </tr> <tr> <td>SQ</td> </tr> <tr> <td>2</td> <td>Control</td> <td>19,100</td> <td>791</td> <td>4.1</td> <td>N/A</td> </tr> <tr> <td></td> <td>SQ</td> <td></td> <td></td> <td></td> <td>N/A</td> </tr> <tr> <td>3</td> <td>SQ</td> <td>24,000</td> <td>542</td> <td>2.3</td> <td>N/A</td> </tr> <tr> <td>3</td> <td>SQ</td> <td>24,029</td> <td>267</td> <td>1.1</td> <td>N/A</td> </tr> <tr> <td rowspan="2">3</td> <td>Control</td> <td rowspan="2">25,000</td> <td rowspan="2">332</td> <td rowspan="2">1.3</td> <td rowspan="4">N/A</td> </tr> <tr> <td>SQ</td> </tr> <tr> <td rowspan="2">3</td> <td>Control</td> <td rowspan="2">25,000</td> <td rowspan="2">325</td> <td rowspan="2">1.3</td> </tr> <tr> <td>SQ</td> </tr> </tbody> </table> <p>N/A is not applicable</p>	Location	Treatment	Total Placed	21 Day Mortality	% Mortality	% Hatchability	1	<i>In ovo</i>	22,600	794	3.5	74.7	1	Control	24,700	721	2.9	87.4	<i>In ovo</i>	1	Control	24,700	815	3.3	<i>In ovo</i>	1	Control	24,700	679	2.7	<i>In ovo</i>	2	<i>In ovo</i>	20,200	398	2	89.3	2	<i>In ovo</i>	20,300	369	1.8	2	Control	19,100	410	2.1	86.6	<i>In ovo</i>	2	Control	19,100	678	3.5	SQ	2	Control	19,100	791	4.1	N/A		SQ				N/A	3	SQ	24,000	542	2.3	N/A	3	SQ	24,029	267	1.1	N/A	3	Control	25,000	332	1.3	N/A	SQ	3	Control	25,000	325	1.3	SQ
Location	Treatment	Total Placed	21 Day Mortality	% Mortality	% Hatchability																																																																																								
1	<i>In ovo</i>	22,600	794	3.5	74.7																																																																																								
1	Control	24,700	721	2.9	87.4																																																																																								
	<i>In ovo</i>																																																																																												
1	Control	24,700	815	3.3																																																																																									
	<i>In ovo</i>																																																																																												
1	Control	24,700	679	2.7																																																																																									
	<i>In ovo</i>																																																																																												
2	<i>In ovo</i>	20,200	398	2	89.3																																																																																								
2	<i>In ovo</i>	20,300	369	1.8																																																																																									
2	Control	19,100	410	2.1	86.6																																																																																								
	<i>In ovo</i>																																																																																												
2	Control	19,100	678	3.5																																																																																									
	SQ																																																																																												
2	Control	19,100	791	4.1	N/A																																																																																								
	SQ				N/A																																																																																								
3	SQ	24,000	542	2.3	N/A																																																																																								
3	SQ	24,029	267	1.1	N/A																																																																																								
3	Control	25,000	332	1.3	N/A																																																																																								
	SQ																																																																																												
3	Control	25,000	325	1.3																																																																																									
	SQ																																																																																												
USDA Approval Date	October 19, 2017																																																																																												